naproxen has been researched along with tacrine in 10 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (tacrine) | Trials (tacrine) | Recent Studies (post-2010) (tacrine) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 2,141 | 161 | 643 |
| Protein | Taxonomy | naproxen (IC50) | tacrine (IC50) |
|---|---|---|---|
| Chain A, ACETYLCHOLINESTERASE | Tetronarce californica (Pacific electric ray) | 0.0082 | |
| Solute carrier family 22 member 2 | Homo sapiens (human) | 0.68 | |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.1401 | |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.1691 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 0.0456 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.7875 | |
| Cytochrome P450 2E1 | Homo sapiens (human) | 0.075 | |
| Cholinesterase | Homo sapiens (human) | 0.0545 | |
| Acyl-CoA desaturase 1 | Rattus norvegicus (Norway rat) | 0.047 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.517 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 6.6 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 6.6 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 6.6 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1084 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 6.6 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.0457 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.3 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 6.6 | |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.0457 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.078 | |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.1957 | |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.0835 | |
| Amine oxidase [flavin-containing] A | Bos taurus (cattle) | 0.047 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.1143 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.2576 | |
| Acetylcholinesterase | Bos taurus (cattle) | 0.1848 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.517 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.1143 | |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | 0.2097 | |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | 0.042 | |
| Cholinesterase | Equus caballus (horse) | 0.1103 | |
| Histamine N-methyltransferase | Rattus norvegicus (Norway rat) | 0.11 | |
| Cholinesterase | Mus musculus (house mouse) | 0.0625 | |
| Acetylcholine receptor subunit epsilon | Homo sapiens (human) | 0.044 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 6.3 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 6.3 | |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | 0.267 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.1 | |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | 0.0995 | |
| Carboxylic ester hydrolase | Equus caballus (horse) | 0.0143 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
10 other study(ies) available for naproxen and tacrine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |